Enzo Biochem (ENZ) 6.76 $ENZ
Why Juno Therapeutics (JUNO) Could Be Positioned for a Slump
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 7:40AM CDT
One stock that you may want to consider dropping is Juno Therapeutics Inc. (JUNO), which has witnessed a significant price decline in the past four weeks
ENZ: 6.76 (+0.04), JUNO: 30.68 (-0.18)
Should You Get Rid of Emergent BioSolutions (EBS) Now?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 7:35AM CDT
One stock that you may want to consider dropping is Emergent BioSolutions (EBS), which has witnessed a significant price decline in the past four weeks
EBS: 30.47 (-0.50), ENZ: 6.76 (+0.04)
5 Low Priced Breakout Stocks with Superlative Returns
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 9:21AM CDT
Betting on breakout stocks is one of the most popular methods used by active investors.
CRNT: 2.10 (-0.11), PRTS: 3.48 (-0.47), ENZ: 6.76 (+0.04), ARIS: 4.79 (-0.25), AUY: 5.84 (+0.07)
TrovaGene Inks Partnership with USC Norris Cancer Center
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 5:05PM CDT
TrovaGene (TROV) recently inked a partnership with the USC Norris Comprehensive Cancer Center, which aims at building a standardized framework for the use of the Trovera system.
ENZ: 6.76 (+0.04), INVA: 12.84 (-0.20), TROV: 5.56 (-0.02), FCSC: 1.04 (+0.02)
Strength Seen in Heska (HSKA): Stock Jumps 5.7% in Session
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 7:35AM CDT
Heska Corporation (HSKA) was a big mover last session, as the company saw its shares rise around 6% on the day.
HSKA: 43.61 (+0.20), ENZ: 6.76 (+0.04)
Enzo Biochem's Life Sciences Unit Reaches $21 Million Patent Infringement Settlement in Delaware With Illumina, Inc.
BusinessWire - Thu Jul 07, 8:15AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc., has reached and finalized a settlement with Illumina, Inc. (Nasdaq: ILMN) that included a payment of $21 million to Enzo in an action brought in Delaware Federal District Court by Enzo alleging infringement of its U.S. Patent No. 7,064,197, entitled System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids.
ENZ: 6.76 (+0.04), ILMN: 166.92 (-3.73)
Enzo Biochem Reports Fiscal Third Quarter Results
BusinessWire - Wed Jun 08, 6:30AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today reported results for the third fiscal quarter and nine months ended April 30, 2016, with strong across the board advances.
ENZ: 6.76 (+0.04)
Enzo Biochem Announces New York State Approval of New Women's Test Based on Proprietary Technology
BusinessWire - Tue Jun 07, 7:30AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that the New York State Department of Health has granted conditional approval for use of Enzo Clinical Labs' AmpiProbe Candidiasis(TM) assay, the Company's second test aimed at the rapidly expanding women's health market and the third to be approved utilizing one of the Company's proprietary technology platforms.
ENZ: 6.76 (+0.04)
Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2016 Results Wednesday, June 8, 2016 at 8:30 AM E.T.
BusinessWire - Fri Jun 03, 3:25PM CDT
Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2016 third quarter results, Wednesday, June 8, 2016, at 8:30 AM E.T.
ENZ: 6.76 (+0.04)
Enzo Biochem's Life Sciences Unit Reaches $35 Million Patent Infringement Settlement in Delaware With Life Technologies Corporation
BusinessWire - Mon May 16, 3:07PM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc., has reached and finalized a settlement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific Inc. (NYSE:TMO), involving payment of $35 million to Enzo in an action brought in Delaware Federal District Court by Enzo alleging infringement of its U.S. Patents Nos. 6,992,180 entitled Oligo- or Polynucleotides Comprising Phosphate Moiety Labeled Nucleotides and 7,064,197 entitled System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids.
LIFE: 3.09 (-0.08), ENZ: 6.76 (+0.04), TMO: 156.44 (-3.12)
Global Toxoplasmosis Diagnostic Testing Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Cepheid, Diamedix, Enzo Biochem - Research and Markets
BusinessWire - Thu Mar 10, 11:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/5jnx43/20162020_world) has announced the addition of the "2016-2020 World Toxoplasmosis Diagnostic Testing Market: Commercial Labs, Hospitals, Physician Offices, Public Health Labs--Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts" report to their offering.
ENZ: 6.76 (+0.04), CPHD: 35.84 (-0.92)
Enzo Biochem Submits AmpiProbe Based Assay Targeted at Women's Health for Approval to New York State Department of Health
BusinessWire - Thu Mar 10, 6:45AM CST
Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has submitted to the New York State Department of Health a validation package for its newest AmpiProbe(TM) based assay -- designed to identify the presence of the most common species of Candida from a single vaginal swab, and the first in a panel of tests aimed at diagnosing multiple women's infectious health issues.
ENZ: 6.76 (+0.04)
Enzo Biochem posts 2Q profit
Automated Insights - Wed Mar 09, 3:29PM CST
NEW YORK (AP) _ Enzo Biochem Inc. (ENZ) on Wednesday reported fiscal second-quarter net income of $6.8 million, after reporting a loss in the same period a year earlier.
ENZ: 6.76 (+0.04)
Enzo Biochem Reports Increased Fiscal Second Quarter Results
BusinessWire - Wed Mar 09, 3:05PM CST
Enzo Biochem, Inc. (NYSE:ENZ) today reported results for the second fiscal quarter and fiscal first half ended January 31, 2016, led by strong gains at Enzo Clinical Labs reflecting increased molecular diagnostic testing demand.
ENZ: 6.76 (+0.04)
Emerging Microbiology Testing Technologies Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Enzo Biochem, Roche, Takara Bio - Research and Markets
BusinessWire - Wed Mar 09, 1:11PM CST
Research and Markets (http://www.researchandmarkets.com/research/m76q69/20162020) has announced the addition of the "2016-2020 Emerging Microbiology Testing Technologies and Strategic Profiles of Leading Suppliers" report to their offering.
ENZ: 6.76 (+0.04)
Crohn's Disease (Regional Enteritis) - Pipeline Review Report H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/crzbr7/crohns_disease) has announced the addition of the "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease (Regional Enteritis)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Crohn's Disease (Regional Enteritis)Overview - Therapeutics Development - Pipeline Products for Crohn's Disease (Regional Enteritis)- Overview - Pipeline Products for Crohn's Disease (Regional Enteritis)- Comparative Analysis - Crohn's Disease (Regional Enteritis)- Therapeutics under Development by Companies - Crohn's Disease (Regional Enteritis)- Therapeutics under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Crohn's Disease (Regional Enteritis)- Products under Development by Companies - Crohn's Disease (Regional Enteritis)- Products under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - BioAtla, LLC - BIOCAD - BioLingus AG - Bionovis SA - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - CLL Pharma - Commence Bio, Inc. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - Eisai Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Enterome Bioscience SA - Enzo Biochem, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/cr...ns_disease
EBS: 30.47 (-0.50), AMGN: 174.15 (-0.01), AMPE: 0.95 (-0.01), LLY: 83.32 (+0.14), ENZ: 6.76 (+0.04), CCXI: 4.63 (-0.04), ABBV: 66.78 (-0.16), ARNA: 1.63 (-0.05), CELGZ: 1.11 (-0.03)
Osteonecrosis Pipeline Review, H2 2015 Featuring Bone Therapeutics SA, Enzo Biochem, Inc. & K-Stemcell Co., Ltd. - Research and Markets
BusinessWire - Thu Feb 04, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/hhjj3t/osteonecrosis) has announced the addition of the "Osteonecrosis - Pipeline Review, H2 2015" report to their offering.
ENZ: 6.76 (+0.04)
United States Infectious Disease Testing Market 2016: Sales and Volume Segment Forecasts for 100 Tests
M2 - Wed Feb 03, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/bxj4vn/2016_u_s) has announced the addition of the "2016 U.S. Infectious Disease Testing Market: Sales and Volume Segment Forecasts for 100 Tests, Supplier Shares by Test, Innovative Technologies, Competitive Strategies, Emerging Opportunities" report to their offering. This new report is a strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years. The report examines key US market trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, and market segment; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers. This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies. Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products. Companies Mentioned - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Elitech Group - Enzo Biochem - Fujirebio - Grifols - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech/Leica - Lonza - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher/Life Technology - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/bxj4vn/2016_u_s
SQNM: 2.36 (unch), ENZ: 6.76 (+0.04), CPHD: 35.84 (-0.92), DHR: 80.93 (-0.57), HOLX: 39.03 (+0.05)
United States Virology and Bacteriology Testing Market 2016: Sales and Volume Segment Forecasts for 100 Tests
M2 - Wed Feb 03, 9:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bj66z3/2016_u_s) has announced the addition of the "2016 U.S. Virology and Bacteriology Testing Market: Sales and Volume Segment Forecasts for 100 Tests, Supplier Shares by Test, Innovative Technologies, Competitive Strategies, Emerging Opportunities" report to their offering. This new report is a strategic analysis of major business opportunities emerging in the infectious disease testing market during the nextfive years. The report examines key US market trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, and market segment; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers. This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies. Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products. Companies Mentioned - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Elitech Group - Enzo Biochem - Fujirebio - Grifols - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech/Leica - Lonza - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher/Life Technology - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/bj66z3/2016_u_s
SQNM: 2.36 (unch), ENZ: 6.76 (+0.04), CPHD: 35.84 (-0.92), DHR: 80.93 (-0.57), HOLX: 39.03 (+0.05)
U.S. HIV/AIDS Diagnostic Testing Market: Supplier Shares and Forecasts 2016
M2 - Wed Feb 03, 9:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/z24z2v/2016_u_s) has announced the addition of the "2016 U.S. HIV/AIDS Diagnostic Testing Market: Supplier Shares and Country Forecasts" report to their offering. This report presents detailed analyses of the AIDS diagnostics market in the US. The report provides test volume and sales forecasts for HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II and other confirmatory tests performed in the following market segments: - Hospitals - Commercial/Private Laboratories - Blood Banks - Physician Offices - Public Health Laboratories In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of AIDS tests. Highlights - Provides scientific views on the definition, epidemiology and etiology of AIDS and other retroviruses. - Examines market applications of Molecular Diagnostics, Immunodiagnostics, IT and other emerging technologies. - Reviews infectious disease testing analyzers marketed by Abbott, Beckman Coulter/Danaher, bioMerieux, Ortho-Clinical Diagnostics/J&J, Roche, Siemens, Tosoh and other suppliers. - Profiles leading manufacturers and potential market entrants developing innovative technologies and products. - Analyzes alternative market penetration strategies for suppliers. Competitive Assessments - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Elitech Group - Enzo Biochem - Fujirebio - Grifols - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech/Leica - Lonza - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher/Life Technology - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/z24z2v/2016_u_s
SQNM: 2.36 (unch), ENZ: 6.76 (+0.04), CPHD: 35.84 (-0.92), DHR: 80.93 (-0.57), HOLX: 39.03 (+0.05)
Why Juno Therapeutics (JUNO) Could Be Positioned for a Slump
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 7:40AM CDT
One stock that you may want to consider dropping is Juno Therapeutics Inc. (JUNO), which has witnessed a significant price decline in the past four weeks
ENZ: 6.76 (+0.04), JUNO: 30.68 (-0.18)
Should You Get Rid of Emergent BioSolutions (EBS) Now?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 7:35AM CDT
One stock that you may want to consider dropping is Emergent BioSolutions (EBS), which has witnessed a significant price decline in the past four weeks
EBS: 30.47 (-0.50), ENZ: 6.76 (+0.04)
5 Low Priced Breakout Stocks with Superlative Returns
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 9:21AM CDT
Betting on breakout stocks is one of the most popular methods used by active investors.
CRNT: 2.10 (-0.11), PRTS: 3.48 (-0.47), ENZ: 6.76 (+0.04), ARIS: 4.79 (-0.25), AUY: 5.84 (+0.07)
TrovaGene Inks Partnership with USC Norris Cancer Center
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 5:05PM CDT
TrovaGene (TROV) recently inked a partnership with the USC Norris Comprehensive Cancer Center, which aims at building a standardized framework for the use of the Trovera system.
ENZ: 6.76 (+0.04), INVA: 12.84 (-0.20), TROV: 5.56 (-0.02), FCSC: 1.04 (+0.02)
Strength Seen in Heska (HSKA): Stock Jumps 5.7% in Session
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 7:35AM CDT
Heska Corporation (HSKA) was a big mover last session, as the company saw its shares rise around 6% on the day.
HSKA: 43.61 (+0.20), ENZ: 6.76 (+0.04)
Enzo Biochem's Life Sciences Unit Reaches $21 Million Patent Infringement Settlement in Delaware With Illumina, Inc.
BusinessWire - Thu Jul 07, 8:15AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc., has reached and finalized a settlement with Illumina, Inc. (Nasdaq: ILMN) that included a payment of $21 million to Enzo in an action brought in Delaware Federal District Court by Enzo alleging infringement of its U.S. Patent No. 7,064,197, entitled System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids.
ENZ: 6.76 (+0.04), ILMN: 166.92 (-3.73)
Enzo Biochem Reports Fiscal Third Quarter Results
BusinessWire - Wed Jun 08, 6:30AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today reported results for the third fiscal quarter and nine months ended April 30, 2016, with strong across the board advances.
ENZ: 6.76 (+0.04)
Enzo Biochem Announces New York State Approval of New Women's Test Based on Proprietary Technology
BusinessWire - Tue Jun 07, 7:30AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that the New York State Department of Health has granted conditional approval for use of Enzo Clinical Labs' AmpiProbe Candidiasis(TM) assay, the Company's second test aimed at the rapidly expanding women's health market and the third to be approved utilizing one of the Company's proprietary technology platforms.
ENZ: 6.76 (+0.04)
Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2016 Results Wednesday, June 8, 2016 at 8:30 AM E.T.
BusinessWire - Fri Jun 03, 3:25PM CDT
Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2016 third quarter results, Wednesday, June 8, 2016, at 8:30 AM E.T.
ENZ: 6.76 (+0.04)
Enzo Biochem's Life Sciences Unit Reaches $35 Million Patent Infringement Settlement in Delaware With Life Technologies Corporation
BusinessWire - Mon May 16, 3:07PM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc., has reached and finalized a settlement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific Inc. (NYSE:TMO), involving payment of $35 million to Enzo in an action brought in Delaware Federal District Court by Enzo alleging infringement of its U.S. Patents Nos. 6,992,180 entitled Oligo- or Polynucleotides Comprising Phosphate Moiety Labeled Nucleotides and 7,064,197 entitled System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids.
LIFE: 3.09 (-0.08), ENZ: 6.76 (+0.04), TMO: 156.44 (-3.12)
Global Toxoplasmosis Diagnostic Testing Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Cepheid, Diamedix, Enzo Biochem - Research and Markets
BusinessWire - Thu Mar 10, 11:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/5jnx43/20162020_world) has announced the addition of the "2016-2020 World Toxoplasmosis Diagnostic Testing Market: Commercial Labs, Hospitals, Physician Offices, Public Health Labs--Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts" report to their offering.
ENZ: 6.76 (+0.04), CPHD: 35.84 (-0.92)
Enzo Biochem Submits AmpiProbe Based Assay Targeted at Women's Health for Approval to New York State Department of Health
BusinessWire - Thu Mar 10, 6:45AM CST
Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has submitted to the New York State Department of Health a validation package for its newest AmpiProbe(TM) based assay -- designed to identify the presence of the most common species of Candida from a single vaginal swab, and the first in a panel of tests aimed at diagnosing multiple women's infectious health issues.
ENZ: 6.76 (+0.04)
Enzo Biochem posts 2Q profit
Automated Insights - Wed Mar 09, 3:29PM CST
NEW YORK (AP) _ Enzo Biochem Inc. (ENZ) on Wednesday reported fiscal second-quarter net income of $6.8 million, after reporting a loss in the same period a year earlier.
ENZ: 6.76 (+0.04)
Enzo Biochem Reports Increased Fiscal Second Quarter Results
BusinessWire - Wed Mar 09, 3:05PM CST
Enzo Biochem, Inc. (NYSE:ENZ) today reported results for the second fiscal quarter and fiscal first half ended January 31, 2016, led by strong gains at Enzo Clinical Labs reflecting increased molecular diagnostic testing demand.
ENZ: 6.76 (+0.04)
Emerging Microbiology Testing Technologies Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Enzo Biochem, Roche, Takara Bio - Research and Markets
BusinessWire - Wed Mar 09, 1:11PM CST
Research and Markets (http://www.researchandmarkets.com/research/m76q69/20162020) has announced the addition of the "2016-2020 Emerging Microbiology Testing Technologies and Strategic Profiles of Leading Suppliers" report to their offering.
ENZ: 6.76 (+0.04)
Crohn's Disease (Regional Enteritis) - Pipeline Review Report H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/crzbr7/crohns_disease) has announced the addition of the "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease (Regional Enteritis)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Crohn's Disease (Regional Enteritis)Overview - Therapeutics Development - Pipeline Products for Crohn's Disease (Regional Enteritis)- Overview - Pipeline Products for Crohn's Disease (Regional Enteritis)- Comparative Analysis - Crohn's Disease (Regional Enteritis)- Therapeutics under Development by Companies - Crohn's Disease (Regional Enteritis)- Therapeutics under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Crohn's Disease (Regional Enteritis)- Products under Development by Companies - Crohn's Disease (Regional Enteritis)- Products under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - BioAtla, LLC - BIOCAD - BioLingus AG - Bionovis SA - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - CLL Pharma - Commence Bio, Inc. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - Eisai Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Enterome Bioscience SA - Enzo Biochem, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/cr...ns_disease
EBS: 30.47 (-0.50), AMGN: 174.15 (-0.01), AMPE: 0.95 (-0.01), LLY: 83.32 (+0.14), ENZ: 6.76 (+0.04), CCXI: 4.63 (-0.04), ABBV: 66.78 (-0.16), ARNA: 1.63 (-0.05), CELGZ: 1.11 (-0.03)
Osteonecrosis Pipeline Review, H2 2015 Featuring Bone Therapeutics SA, Enzo Biochem, Inc. & K-Stemcell Co., Ltd. - Research and Markets
BusinessWire - Thu Feb 04, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/hhjj3t/osteonecrosis) has announced the addition of the "Osteonecrosis - Pipeline Review, H2 2015" report to their offering.
ENZ: 6.76 (+0.04)
United States Infectious Disease Testing Market 2016: Sales and Volume Segment Forecasts for 100 Tests
M2 - Wed Feb 03, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/bxj4vn/2016_u_s) has announced the addition of the "2016 U.S. Infectious Disease Testing Market: Sales and Volume Segment Forecasts for 100 Tests, Supplier Shares by Test, Innovative Technologies, Competitive Strategies, Emerging Opportunities" report to their offering. This new report is a strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years. The report examines key US market trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, and market segment; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers. This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies. Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products. Companies Mentioned - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Elitech Group - Enzo Biochem - Fujirebio - Grifols - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech/Leica - Lonza - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher/Life Technology - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/bxj4vn/2016_u_s
SQNM: 2.36 (unch), ENZ: 6.76 (+0.04), CPHD: 35.84 (-0.92), DHR: 80.93 (-0.57), HOLX: 39.03 (+0.05)
United States Virology and Bacteriology Testing Market 2016: Sales and Volume Segment Forecasts for 100 Tests
M2 - Wed Feb 03, 9:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bj66z3/2016_u_s) has announced the addition of the "2016 U.S. Virology and Bacteriology Testing Market: Sales and Volume Segment Forecasts for 100 Tests, Supplier Shares by Test, Innovative Technologies, Competitive Strategies, Emerging Opportunities" report to their offering. This new report is a strategic analysis of major business opportunities emerging in the infectious disease testing market during the nextfive years. The report examines key US market trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, and market segment; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers. This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies. Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products. Companies Mentioned - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Elitech Group - Enzo Biochem - Fujirebio - Grifols - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech/Leica - Lonza - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher/Life Technology - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/bj66z3/2016_u_s
SQNM: 2.36 (unch), ENZ: 6.76 (+0.04), CPHD: 35.84 (-0.92), DHR: 80.93 (-0.57), HOLX: 39.03 (+0.05)
U.S. HIV/AIDS Diagnostic Testing Market: Supplier Shares and Forecasts 2016
M2 - Wed Feb 03, 9:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/z24z2v/2016_u_s) has announced the addition of the "2016 U.S. HIV/AIDS Diagnostic Testing Market: Supplier Shares and Country Forecasts" report to their offering. This report presents detailed analyses of the AIDS diagnostics market in the US. The report provides test volume and sales forecasts for HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II and other confirmatory tests performed in the following market segments: - Hospitals - Commercial/Private Laboratories - Blood Banks - Physician Offices - Public Health Laboratories In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of AIDS tests. Highlights - Provides scientific views on the definition, epidemiology and etiology of AIDS and other retroviruses. - Examines market applications of Molecular Diagnostics, Immunodiagnostics, IT and other emerging technologies. - Reviews infectious disease testing analyzers marketed by Abbott, Beckman Coulter/Danaher, bioMerieux, Ortho-Clinical Diagnostics/J&J, Roche, Siemens, Tosoh and other suppliers. - Profiles leading manufacturers and potential market entrants developing innovative technologies and products. - Analyzes alternative market penetration strategies for suppliers. Competitive Assessments - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Elitech Group - Enzo Biochem - Fujirebio - Grifols - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech/Leica - Lonza - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher/Life Technology - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/z24z2v/2016_u_s
SQNM: 2.36 (unch), ENZ: 6.76 (+0.04), CPHD: 35.84 (-0.92), DHR: 80.93 (-0.57), HOLX: 39.03 (+0.05)
